The American Society of Clinical Oncology (ASCO) Annual Meeting stands as one of the most influential gatherings in clinical oncology, offering a critical platform for presenting clinical studies that have the potential to shape future practice and research. This year, ASCO will be held from May 31st to June 4th, 2024 in Chicago Illinois. Geneseeq will participate in the ASCO with five interesting topics covering the identification of novel biomarkers and early detection of diverse cancer types.


The following is a summary of our studies that will be presented at ASCO 2024:

Poster 1 (Bd# 276) A multi-center study for colorectal cancer early detection among patients with high-risk disease using a cell-free fragmentomics assay.

Poster 2 (Bd# 34) Leveraging cfDNA fragmentomic features in a stacked ensemble model for early detection of esophageal squamous cell carcinoma.

Poster 3 (Bd# 153) Fragmentomics of cell-free DNA as a sensitive biomarker for early detection of pancreatic cancer.

Poster 4 (Bd# 83) Molecular characterization and biomarker identification in pediatric B-cell acute lymphoblastic leukemia.

Poster 5 (Bd# 460) Genomic profiling of non-small cell lung cancer with rare aberrations in EGFR codon L858 and the survival outcome under real-world first-line EGFR tyrosine kinase inhibitor treatment compared to classic EGFRL858R